HSPA5 and esophageal squamous cell carcinoma: In addition, to elucidate how GRP78 binding influences ESCC progression via lnc191 in vivo, we developed animal models utilizing KYSE‐30 cells with stable overexpression of lnc191 and the GRP78 inhibitor HA15 (Figure 5H).